The ADC Cytotoxic Payloads / Warheads market

 

The “ADC Cytotoxic Payloads / Warheads market, 2021-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of ADC Cytotoxic Payloads / Warheads service providers, over the next decade.

 

To order this 130+ page report, please visit

https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

 

Key Inclusions

§  A review of the overall market landscape of the companies offering ADC payloads and warheads, featuring a detailed analysis based on the type of payload, type of microtubule inhibitors, DNA damaging agents and toposimerase inhibitors. In addition, it includes information on the developer’s year of establishment, and location of headquarters and company size of the players.

§  Elaborate profiles of players involved in the manufacturing of ADC payloads and warheads. Each profile features a brief overview of the company, its facility location, its financial information (if available), recent developments, and an informed future outlook.

§  An analysis of the partnerships that have been established in this domain since 2016, covering instances of licensing agreements, R&D agreements, mergers / acquisitions, manufacturing and supply agreements, product development agreements, service alliance, product development and commercialization agreements, and other relevant types of deals.

§  An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies focused on the development of ADC payloads and warheads.

§  A review of the expansions that have undertaken by the players engaged in developing ADC payloads and warheads for enhancing their respective offerings. It features a detailed analysis based on a number of parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), location of facility and leading players.

§  An in-depth analysis of the various patents that have been filed / granted related to ADC payloads and warheads, highlighting key trends across the parameters, such as publication year, patent type, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry players (in terms of size of intellectual property portfolio). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

§  An informed estimate of the annual clinical / commercial demand for ADC paylaods and warheads (in kilograms), taking into account parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

§  A case study on the ADCs that are already approved and those that are under development (clinical and preclinical), providing information on their phase of development (approved, clinical and preclinical / discovery stage), therapeutic area, line of treatment, dosing regimen, targetantigen, antibody isotype, type of linker, type of payload / warhead and type of payload category. In addition, it provides a list of ADC developers, along with information on their year of establishment, company size and geography. The chapter also highlights the key players (in terms of number of drugs developed) in this industry.

 

Key Questions Answered

§  Who are the leading players engaged in the development of ADC cytotoxic payloads / warheads?

§  What kind of partnership models are commonly adopted by industry stakeholders engaged in the ADC cytotoxic payloads / warheads domain?

§  Which key investors are likely to drive the development efforts related to ADC cytotoxic payloads / warheads?

§  How has the intellectual property landscape of ADC cytotoxic payloads / warheads evolved over the years?

§  How is the current and future opportunity likely to be distributed across key market segments?              

 

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 

The financial opportunity within the ADC cytotoxic payloads / warheads market has been analyzed across the following segments:

§  Type of Payload

• Microtubule Inhibitors
• DNA Damaging Agents
• Topoisomerase Inhibitors

 

§  Payload

• Auristatins
• Camptothecin
• Maytansinoids

 

§  Type of Product

• Commercialized Products
• Clinical Products

 

§  Key Geographical Regions 

• North America
• Europe
• Asia Pacific

 

 

The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the ADC cytotoxic payloads / warheads market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms.

 

 

The report also includes detailed profiles of the companies (listed below) engaged in developing ADC cytotoxic payloads / warheads; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.

§  Abzena

§  Levana Biopharma

§  MabPlex

§  NJ Bio

§  Novasep

§  STA Pharmaceuticals

§  Synaffix

 

For additional details, please visit

https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.    Antibody Drug Conjugates Market, 2021-2030

2.     Biologics Fill / Finish Services Market, 2021-2030

3.     Global Antibody Purification Services Market,  2021-2030

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com